Phase III results: tiotropium* Respimat® effective in symptomatic asthma patients despite at least ICS†/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response
For Media outside the U.S., Canada and UK
Change in the Board of Managing Directors at Boehringer Ingelheim
ASCO 2013: Boehringer Ingelheim to present highly anticipated new Phase III results for front-runner compounds afatinib* and nintedanib* in first- and second-line NSCLC treatment
ASCO 2013: New Phase III data reveal targeted treatment with afatinib* or with nintedanib* improves progression-free survival in patients with advanced NSCLC
For non U.S. Media Only
Boehringer Ingelheim joins Structural Genomics Consortium - for further research into uncurable diseases
